CA
NZ
UK
AU
IND
US
U.S. Vice President JD Vance has portrayed artificial intelligence as a catalyst for extraordinary economic growth, stressing that its advantages need to be equitably distributed to avoid the stark disparities witnessed during earlier periods of rapid technological change. During a recent conversation on a …
The 2026 midyear outlook warns that the AI boom is sharpening a fundamental split between scarcity and abundance across the global economy. Rising demand for high‑performance processors, edge‑computing hardware and low‑latency networks is colliding with constrained supplies of semiconductors, rare earths and renewable‑energy components. …
AI Era Corp. The decision, effective immediately, leaves Deng overseeing all three roles. The shift marks the latest in a series of leadership adjustments at the company, which has disclosed a dozen officer or director changes.
Incyte Corporation (NASDAQ: INCY) is scheduled to present two separate Phase 3 oncology readouts at the ESMO 2026 congress, covering candidates in pancreatic cancer and ovarian cancer.
Kalaris Therapeutics (NASDAQ: KLRS) presented Phase 1a data at the ASRS meeting on July 17, 2026, showing significant gains in visual acuity and retinal thickness for its neovascular age-related macular degeneration candidate, TH103.
Veradermics Incorporated (NASDAQ: MANE) shares closed up 5.19% at $111.32 after the company shared Phase 2/3 data for its male pattern hair loss candidate VDPHL01 at the AAD Innovation Academy on July 17, 2026.
Isoray (NASDAQ: CATX) is scheduled to present Phase 1 data covering cohorts 1 through 3 for its radiopharmaceutical candidate [212Pb]VMT-α-NET in neuroendocrine tumors at the ESMO 2026 congress on October 23.
Agenus Inc. (NASDAQ: AGEN) is scheduled to present Phase 2 results from its NEOASIS study of neoadjuvant BOT/BAL in MMR-deficient colorectal cancer at the ESMO 2026 congress on October 25.
IDEAYA Biosciences (NASDAQ: IDYA) is scheduled to present first Phase 1 data for IDE849, also known as SHR-4849, in solid tumors and small cell lung cancer at the ESMO 2026 congress, running October 23-27.
Merck & Company (NYSE: MRK) is set to present three-year Phase 2 data on its personalized cancer vaccine EVX-01, used in combination with KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab), at the ESMO 2026 congress running October 23-27.
Please wait processing your request...